21st International Symposium on Infections in the Critically Ill Patient

Start

Fri, 12 Feb 2016, 10:00

End

Sat, 13 Feb 2016, 06:50

WebSite

http://www.infections-online.es/

Venue:

KEYNOTE SPEAKERS

Prof. Antonio Artigas, MD, PhD

ICU Management & Practice Editorial Board Member

******@***cspt.es

Dept. of Intensive Care Medicine Hospital de Sabadell - CIBER de Enfermedades Respiratorias Corporació Sanitaria I Universitària Parc Taulí Sabadell, Spain

Prof Thierry Calandra

******@***chuv.ch

Centre Hospitalier Universitaire Vaudois

Prof. Massimo Antonelli, MD

******@***rm.unicatt.it

Past President - Italian Society of Intensive Care Medicine and Anesthesiology
Chair, Dept. of Anesthesiology and Intensive Care Medicine - Catholic University of Rome A. Gemelli University Hospital
President - European Society of Intensive Care Medicine (2016-2018)

Prof Matteo Bassetti

******@***tin.it

University Hospital San Maria della Misericordia

Prof. John Kellum, MD, FACP, FCCM

Editorial Board Member since 2013

******@***ccm.upmc.edu

Professor and Vice Chair for Research - University of Pittsburgh, School of Medicine, Department of Critical Care Medicine

Exhibit

Symposia

Workshops

Organiser

Sponsor

The aim of this two days symposium is to review current concepts, technology and present advances in infections in the critically ill patients.
Sepsis, Pulmonary Infections, Basic Research, Pulmonary Infections Treatment and Prophylaxis Therapy of severe infections will be the topics of the main sessions presented by experts who will review and update the new advances on infections in the critically ill patient. At the end of each session a Clinical Controversy, Pannel Discussion or Case Report Discussion will be organized.

ENDORSED BY

	Prior to 31/12/2015	After 31/12/2015
*MEMBERS	350€	450€
NON MEMBERS	420€	520€
**RESIDENTS	250€	300€

The following registration fees include access to the Scientific Sessions and the Commercial Exhibition, Conference documents, Certificate of Attendance and Coffee Breaks

* Members of the Associations endorsing the Symosium
** A letter signed by the institution responsible is required to get this fee.

REGISTRATION FORM

Registration by Mail or Fax
Please fill this form (type or block capital letters) PDF Registration Form mail it or fax it directly to the Symposium Technical Secretariat

CANCELATION POLICY

Cancellations must be sent in written to the Technical Secretariat before January 15th, 2016. An administration fee of 30 euros will be debited as management expenses. No fees will be refunded after this date. The participant acknowledges that he/she has no right to lodge damage claims against the organizers and should the holding if the Congress be hindered or prevented by unexpected, political or economic events or generally by force majeure, or should the nonappearance of speakers or other reasons necessitate program changes. With reservation, the participant accepts this proviso.


Friday, February 12th, 2016

10:00	Introduction
	A. Artigas, MD (Sabadell, Spain)
	J. Carlet, MD (Paris, France)
	M. Niederman, MD (New York, USA)
	A. Torres, MD (Barcelona, Spain)

I. SEPSIS
Moderators:
A. Artigas, MD (Sabadell, Spain)
D. Payen, MD (Paris, France)

10:10	Cardiac dysfunction in severe sepsis M. Cecconi, MD (London, UK)
10:40	Bolus fluid resuscitation in severe sepsis X. Monnet, MD (Paris, France)
11:00	Is SIRS dead? New definition of sepsis M. Singer, MD (London, Uk)
11:20	The elderly patients admitted to the ICU with sepsis R. Curtis, MD (Seattle, USA)
11:40	Dropping mortality in sepsis and its impact on clinical trials R. Ferrer, MD (Barcelona, Spain)
12:00	Break
12:30	Debate: It is unethical to do more clinical trials in sepsis?
	Moderator:
	M. Singer, MD (London, Uk)
	Pro: R. Curtis, MD (Seattle, USA)
	Con: JL. Vincent, MD (Brussels, Belgium)

II. FROM THE PHYSIOPATHOLOGY TO THE BEDSIDE
Moderators: H. Gerlach, MD (Berlin, Germany)
J. Pugin, MD (Genève, Switzerland)

14:00	Clinical evidence of cell metabolic abnormalities in sepsis: myth or reality M. Singer, MD (London, UK)
14:20	The impact of proteonomics and metabolomics for search of biomarkers in severe infections JA. Lorente, MD (Getafe, Spain)
14:40	Should we measure blood immunoglobulin level? I. Martín-Loeches, MD (Dublin, Ireland)
15:00	Sepsis-induced organ failure: what can we learn from histology? R. Herrero, MD (Getafe, Spain)
15:20	Stem cells in sepsis and acute lung injury: A new horizon R. Guillamat, MD (Sabadell, Spain)
15:40	How fluids influence the host response D. Payen, MD (Paris, France)
16:00	Break
16:30	AKI in severe sepsis J. Kellum, MD (Pittsburgh, USA)
16:50	Regional vs systemic hemodynamics in severe sepsis C. Ince, MD (Amsterdam, Netherlands)
17:10	New therapeutic strategies in severe sepsis and septic shock JL. Vincent, MD (Brussels, Belgium)

Saturday, February 13th, 2016

III. PULMONARY INFECTIONS
Moderators: J. Chastre, MD (Paris, France)
A. Torres, MD (Barcelona, Spain)

09:00	The lung response to acute and repeated bacterial challenge M. Schultz, MD (Amsterdam, Netherlands)
09:20	The lung microbiones: New frontiers? T. Calandra, MD (Lausanne, Switzerland)
09:40	Corticosteroids in severe CAP: what is next A. Torres, MD (Barcelona, Spain)
10:00	Control of endotracheal tube cuff pressure S. Nseir, MD (Lille, France)
10:20	VAP Gravity Trial GL. Li Bassi, MD (Barcelona, Spain)
10:40	Prevention of nosocomial pneumonia: Does one size fit all? M. Antonelli, MD (Rome, Italy)
11:00	Breathomics to diagnose VAP L. Bos, MD (Amsterdam, Netherlands)
11:20	Biomarkers in the assessment of VAP response to antibiotics P. Povoa, MD (Lisboa, Portugal)
11:40	Chosing the right moment to start antibiotic treatment in VAP P. Ramirez, MD (Valencia, Spain)
12:00	Break
12:30	Debate: Treatment is needed for ventilator-associated bronchitis Moderator: I.Martín-Loeches (Dublin, Ireland) Pro: S. Nseir, MD (Lille, France) Con: J. Chastre, MD (Paris, France)

IV. TREATMENT AND PROPHYLAXIS
Moderators: J. Carlet, MD (Paris, France) JA. Paiva, MD (Oporto, Portugal)

14:00	Can VAP be used as a quality indicator? M. Niederman, MD (New York, USA)
14:20	SOD, SDD, or something else, everywhere, or only in HIC? M. Schultz, MD (Amsterdam, Netherlands)
14:40	Pneumococal conjugated PCV13 vaccine (The CAPITA study)
15:00	Pentaglobulin in severe CAP (The CIGMA Trial) T. Welte, MD (Hannover, Germany)
15:20	Meropenen vs Colistine in VAP: a multicenter study M. Antonelli, MD (Rome, Italy)
15:40	Debate: De-escalation of empirical antibiotic therapy for all? Moderator: M. Ferrer, MD (Barcelona, Spain) Pro: J. Garnacho, MD (Sevilla, Spain) Con: M. Leone, MD (Marseille, France)
16:10	New antimicrobial utilization strategies in the ICU M. Niederman, MD (New York, USA)
16:30	Physicians and industry: the broader implications R. Curtis, MD (Seattle, USA)
16:50	Closing Remarks


Friday, February 12th, 2016

13:00-14:00
FLUIDS IN SEPSIS
Moderator: C.Martin, MD (Marseille, France)

13:00	Should we ban balanced fluids until we have good evidence that is safe (to prevent fluid debacle)? M. Schultz, MD (Amsterdam, The Netherlands)
13:20	Volume status and fluid resuscitation what's the solution? JL. Vincent, MD (Brussels, Belgium)
13:40	Discussion


17:00-18:20
EXTRACORPOREAL THERAPIES IN SEVERE SEPSIS
Moderator: A.Artigas, MD (Sabadell, Spain)

17:30	Absorption or filtration? J. Kellum, MD (Pittsburgh, USA)
17:50	Polymixin B hemoperfusion: a therapy for septic shock? M. Antonelli, MD (Rome, Italy)
18:10	Discussion


Saturday, February 13th, 2016

13:00-14:00
MULTIRESISTANT DRUG MICROORGANISMS INFECTIONS
Moderator: M. Niederman, MD (New York, USA)

13:00	MRSA Management: The GLIMP study S. Aliberti, MD (Monza, Italy)
13:20	How to treat multiresistent pseudomonas J.Garnacho, MD (Sevilla, Spain)
13:40	Carbapenemase producing enterobacteria M. Bassetti, MD (Udine, Italy)